Compartir
Este es el nuevo punto de información pensado para personal médico y pacientes sobre coronavirus de Elsevier. Aquí encontrará información experta y de calidad para la comunidad científica y los profesionales de la salud sobre el nuevo coronavirus (también denominado COVID-19 y 2019-nCoV)
Todos los recursos son de libre acceso para personal sanitario y pacientes.
Seleccione una especialidad
Biological therapy as an alternative treatment for cytokine release syndrome in patients with COVID-19
Urbano Solis Cartas
10.1016/j.rcreue.2020.06.012
Rev Colomb Reumatol. 2022;29:74-5
Acceso a texto completo
Clinical characterization of patients with inflammatory myopathy in 2 tertiary care hospitals in Colombia: A descriptive survey
Guillermo Salazar-Villa, Catalina Rodríguez-Prada, Melissa Bonfante-Tamara, Ricardo Restrepo-Correa, Libia María Rodríguez-Padilla, Miguel Antonio Mesa-Navas, Carlos Jaime Velásquez-Franco
10.1016/j.rcreue.2020.09.005
Rev Colomb Reumatol. 2022;29:9-18
Acceso a texto completo
COVID-19 pandemic and blood transfusion services: The impact, response and preparedness experience of a tertiary care blood center in southern Karnataka, India
Dhivya Kandasamy, Shamee Shastry, Deepika Chenna, Ganesh Mohan
10.1016/j.htct.2021.09.019
Hematol Transfus Cell Ther. 2022;44:17-25
Open access
Can SARS-CoV-2 induce hematologic malignancies in predisposed individuals? A case series and review of the literature
Bruno Almeida Costa, Kaiza Vilarinho da Luz, Sarah Emanuelle Viana Campos, Germison Silva Lopes, João Paulo de Vasconcelos Leitão, Fernando Barroso Duarte
10.1016/j.htct.2021.11.015
Hematol Transfus Cell Ther. 2022;44:26-31
Open access
Regarding management of COVID-19 in acute lymphoblastic leukemia
Mohammad Ammad Ud Din
10.1016/j.htct.2021.08.004
Hematol Transfus Cell Ther. 2022;44:120-1
Open access
Response to queries about “COVID-19 and adult acute lymphoblastic leukemia: Presentation and management”
Ayesha Butt, Natasha Ali
10.1016/j.htct.2021.08.009
Hematol Transfus Cell Ther. 2022;44:122-3
Open access
SARS-COV-2 screening in allogeneic hematopoietic stem cell donors: Implications for the evaluation process and eligibility
Roberto Crocchiolo, Francesco Alfarano, Elisabetta Volpato, Mariateresa Pugliano, Irene Cuppari, Anna Maria Mazza, Laura Bellio, Diana Fanti, Chiara Vismara, Francesco Scaglione, Nicoletta Sacchi, Simona Pollichieni, Lia Mele, Elisa Diral, Giovanni Grillo, Silvano Rossini
10.1016/j.htct.2021.09.017
Hematol Transfus Cell Ther. 2022;44:13-6
Open access
Antibody response against SARS-CoV-2 in convalescent plasma donors: Can we predict subjects’ eligibility?
Tiago Paiva Prudente, Renato Gomes Castro, Marcos Antonio Candido, Roberta Luiza Rodrigues, Layane Marques de Souza, Maria do Rosario Ferraz Roberti
10.1016/j.htct.2021.07.008
Hematol Transfus Cell Ther. 2022;44:1-6
Open access
SARS-COV-2: is it a risk for blood transfusion?
Dante Mário Langhi, Renato Cerqueira de Souza, Melca Barros, Gil Cunha De Santis, Simone Haddad Kashima, Jose Orlando Bordin
10.1016/j.htct.2021.08.001
Hematol Transfus Cell Ther. 2022;44:100-3
Open access
Effect of ABO blood groups on length of hospital stay according to age in Covid-19 patients
Vildan Gursoy, Suna Avci
10.1016/j.htct.2021.08.013
Hematol Transfus Cell Ther. 2022;44:7-12
Open access